ClinicalTrials.gg
CompletedNCT06932315Updated Mar 6, 2026

A Study to Evaluate the Safety, Tolerability and Dose-Response Relationship of HRS-9190 in Healthy Subjects

A Phase 1 interventional study of HRS-9190 for Injection in Skeletal Muscle Relaxation, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a single-center, open-label and dose-escalation study to evaluate the safety, tolerability and dose-response relationship of HRS-9190 in healthy adults.

02

Conditions studied

  • Skeletal Muscle Relaxation
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects aged 18 to 45 years (inclusive).
  2. Subjects must have no pregnancy plans for the next three months and agree to use highly effective throughout the trial period.
  3. Capable of understanding the study requirements and willing to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Presence of any condition that could interfere with trial participation.
  2. History or current diagnosis of neuromuscular disorders.
  3. Major surgery within 6 months pre-screening, or planned surgical procedures during the study.
  4. Vaccination received within 1 month prior to screening or planned vaccination during the trial period.
  5. Participation in another drug trial within 3 months pre-screening.
  6. Clinically significant abnormalities in screening/baseline physical examinations.
  7. Positive alcohol breath test at screening.
  8. Pregnancy or lactation status (for female subjects).
  9. Investigator-determined unsuitability for study participation or predicted protocol non-compliance.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    HRS-9190 Experimental Group

    Drug: HRS-9190 for Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Time frame: From the ICF signing date to Day 7.

Secondary outcomes

  1. The maximum observed concentration of HRS-9190 (Cmax)

    Time frame: 0 hour to 1.5 hours after administration.

  2. Time to Cmax of HRS-9190 (Tmax)

    Time frame: 0 hour to 1.5 hours after administration.

  3. Terminal elimination half-life of HRS-9190 (t1/2)

    Time frame: 0 hour to 1.5 hours after administration.

07

Study locations

1 site
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Aug 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Apr 17, 2025
StartActual
Apr 23, 2025
Primary completionActual
Aug 13, 2025
CompletionActual
Aug 13, 2025
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06932315
Responsible party
Sponsor
First posted
Apr 17, 2025
Start date
Apr 23, 2025
Primary completion
Aug 13, 2025
Completion
Aug 13, 2025
Last update
Mar 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9190

Start the discussion